VOR BIOPHARMA INC (VOR) Fundamental Analysis & Valuation

NASDAQ:VOR • US9290332074

Current stock price

13 USD
-0.72 (-5.25%)
At close:
13.01 USD
+0.01 (+0.08%)
After Hours:

This VOR fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. VOR Profitability Analysis

1.1 Basic Checks

  • In the past year VOR has reported negative net income.
  • In the past year VOR has reported a negative cash flow from operations.
  • In the past 5 years VOR always reported negative net income.
  • In the past 5 years VOR always reported negative operating cash flow.
VOR Yearly Net Income VS EBIT VS OCF VS FCFVOR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

  • VOR has a worse Return On Assets (-1389.92%) than 95.37% of its industry peers.
Industry RankSector Rank
ROA -1389.92%
ROE N/A
ROIC N/A
ROA(3y)-57.36%
ROA(5y)-53.18%
ROE(3y)-78.63%
ROE(5y)-74.06%
ROIC(3y)N/A
ROIC(5y)N/A
VOR Yearly ROA, ROE, ROICVOR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300 -400

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for VOR so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
VOR Yearly Profit, Operating, Gross MarginsVOR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. VOR Health Analysis

2.1 Basic Checks

  • VOR has more shares outstanding than it did 1 year ago.
  • The number of shares outstanding for VOR has been increased compared to 5 years ago.
  • VOR has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
VOR Yearly Shares OutstandingVOR Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M
VOR Yearly Total Debt VS Total AssetsVOR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

  • VOR has an Altman-Z score of -28.54. This is a bad value and indicates that VOR is not financially healthy and even has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of -28.54, VOR is doing worse than 87.45% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -28.54
ROIC/WACCN/A
WACCN/A
VOR Yearly LT Debt VS Equity VS FCFVOR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M

2.3 Liquidity

  • VOR has a Current Ratio of 9.16. This indicates that VOR is financially healthy and has no problem in meeting its short term obligations.
  • The Current ratio of VOR (9.16) is better than 77.41% of its industry peers.
  • A Quick Ratio of 9.16 indicates that VOR has no problem at all paying its short term obligations.
  • VOR has a better Quick ratio (9.16) than 77.41% of its industry peers.
Industry RankSector Rank
Current Ratio 9.16
Quick Ratio 9.16
VOR Yearly Current Assets VS Current LiabilitesVOR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. VOR Growth Analysis

3.1 Past

  • VOR shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -85.24%.
EPS 1Y (TTM)-85.24%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%58.38%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to grow by 14.21% on average over the next years. This is quite good.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-278.79%
EPS Next 2Y35.57%
EPS Next 3Y22.56%
EPS Next 5Y14.21%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
VOR Yearly Revenue VS EstimatesVOR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2028 2029 2030 2031 2032 2033 500M 1B
VOR Yearly EPS VS EstimatesVOR Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 -100 -200

More info and screens

Find the best growth stocksShow best growing peers

1

4. VOR Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for VOR. In the last year negative earnings were reported.
  • Also next year VOR is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
VOR Price Earnings VS Forward Price EarningsVOR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
VOR Per share dataVOR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -20 -40 -60

4.3 Compensation for Growth

  • VOR's earnings are expected to grow with 22.56% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y35.57%
EPS Next 3Y22.56%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. VOR Dividend Analysis

5.1 Amount

  • No dividends for VOR!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

VOR Fundamentals: All Metrics, Ratios and Statistics

VOR BIOPHARMA INC

NASDAQ:VOR (3/18/2026, 8:00:01 PM)

After market: 13.01 +0.01 (+0.08%)

13

-0.72 (-5.25%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-18
Earnings (Next)05-12
Inst Owners55.44%
Inst Owner Change566.28%
Ins Owners0.01%
Ins Owner Change-40.3%
Market Cap539.76M
Revenue(TTM)N/A
Net Income(TTM)-2.45B
Analysts83.64
Price Target39.44 (203.38%)
Short Float %9.23%
Short Ratio4
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-197.99%
Min EPS beat(2)-394.6%
Max EPS beat(2)-1.38%
EPS beat(4)0
Avg EPS beat(4)-115.27%
Min EPS beat(4)-394.6%
Max EPS beat(4)-1.38%
EPS beat(8)3
Avg EPS beat(8)-56.4%
EPS beat(12)4
Avg EPS beat(12)-37.86%
EPS beat(16)6
Avg EPS beat(16)-27.88%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-3.33%
EPS NQ rev (1m)0%
EPS NQ rev (3m)57.18%
EPS NY rev (1m)0%
EPS NY rev (3m)-561.56%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-61.13
EYN/A
EPS(NY)-5.51
Fwd EYN/A
FCF(TTM)-3.48
FCFYN/A
OCF(TTM)-3.47
OCFYN/A
SpS0
BVpS-53.6
TBVpS-53.6
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -1389.92%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-57.36%
ROA(5y)-53.18%
ROE(3y)-78.63%
ROE(5y)-74.06%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 18.75%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 9.16
Quick Ratio 9.16
Altman-Z -28.54
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)123.83%
Cap/Depr(5y)265.1%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-85.24%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%58.38%
EPS Next Y-278.79%
EPS Next 2Y35.57%
EPS Next 3Y22.56%
EPS Next 5Y14.21%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-211.02%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-207.98%
EBIT Next 3Y-22.64%
EBIT Next 5YN/A
FCF growth 1Y-50.87%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-52.18%
OCF growth 3YN/A
OCF growth 5YN/A

VOR BIOPHARMA INC / VOR Fundamental Analysis FAQ

What is the fundamental rating for VOR stock?

ChartMill assigns a fundamental rating of 1 / 10 to VOR.


What is the valuation status for VOR stock?

ChartMill assigns a valuation rating of 1 / 10 to VOR BIOPHARMA INC (VOR). This can be considered as Overvalued.


How profitable is VOR BIOPHARMA INC (VOR) stock?

VOR BIOPHARMA INC (VOR) has a profitability rating of 0 / 10.


What is the financial health of VOR BIOPHARMA INC (VOR) stock?

The financial health rating of VOR BIOPHARMA INC (VOR) is 3 / 10.


What is the earnings growth outlook for VOR BIOPHARMA INC?

The Earnings per Share (EPS) of VOR BIOPHARMA INC (VOR) is expected to decline by -278.79% in the next year.